Drug details
Enspryng (satralizumab-mwge injection for subcutaneous administratio)
type of Monoclonal Antibodies
Enspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist used to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
This drug may have the following side effects:
- rash,
- nausea
- upper respiratory tract infection,
- joint pain,
- headache,
- runny or stuffy nose,
- fatigue, and
- gastritis,
- extremity pain,
The following drugs are related to Enspryng, either as a replacement or used together:
- Uplizna (inebilizumab-cdon injection)